Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Immunotherapy has revolutionized cancer treatment and substantially improved patient
outcome with regard to multiple tumour types. However, most patients still do not benefit …

Interactions between T cell receptors (TCRs) and their cognate tumour antigens are central
to antitumour immune responses,–; however, the relationship between phenotypic …

Summary CD4 T follicular helper (TFH) cells support B cells, which are critical for germinal
center (GC) formation, but the importance of TFH-B cell interactions in cancer is unclear. We …

Cancer immunotherapy works by stimulating and strengthening the body's anti-tumor
immune response to eliminate cancer cells. Over the past few decades, immunotherapy has …

Although mutations in DNA are the best-studied source of neoantigens that determine
response to immune checkpoint blockade, alterations in RNA splicing within cancer cells …

T cell receptor (TCR) signal strength is a key determinant of T cell responses. We developed
a cancer mouse model in which tumor-specific CD8 T cells (TST cells) encounter tumor …

Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …

The CD155/TIGIT axis can be co-opted during immune evasion in chronic viral infections
and cancer. Pancreatic adenocarcinoma (PDAC) is a highly lethal malignancy, and immune …

Immune evasion is a hallmark of cancer and therapies that restore immune surveillance
have proven highly effective in cancers with high tumor mutation burden (TMB)(for example …